¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"flow sensitive gradient echo sequence"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • gradient refocused imaging
    ±â¿ï±âÀçÃÊÁ¡¿µ»ó
  • gradient shielding
    °æ»çÂ÷Æó
  • gradient slope
    °æ»ç±â¿ï±â
  • gas flow
    1. °¡½ºÈ帧 2. °¡½ºÀ¯·®
  • gas flow meter
    ±âüÀ¯·®°è
  • high flow method
    °íÀ¯·®¹ý
  • high intensity proton flow
    °í°­µµ¾çÀÚÈ帧, °í°­µµ¾çÀÚÀ¯µ¿
  • ion gradient
    À̿±â¿ï±â, À̿°æ»ç
  • imaging gradient
    ¿µ»ó±â¿ï±â
  • inspiratory triggering flow
    µé¼ûÀ¯¹ß±â·ù
  • kettle flow
    ÄÉÆ²À¯·®
  • laminar flow
    °áÈ帧, ÃþÆÇ·ù
  • minimal current gradient
    ÃÖ¼ÒÀü·ù±â¿ï±â, ÃÖ¼ÒÀü·ù°æ»ç
  • motion compensation gradient
    ¿îµ¿º¸»ó±â¿ï±â
  • maximal expiratory flow
    Ãִ볯¼ûÀ¯·®, ÃÖ´ëÈ£±â·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • slice selection gradient
    ÀýÆí¼±Åñâ¿ï±â
  • spoiler gradient
    ȸ¼Õ±â¿ï±â
  • susceptibility gradient
    °¨¼ö¼º±â¿ï±â
  • ventricular gradient
    ½É½Ç°æ»ç
  • magnetic field gradient vector
    ÀÚÀå±â¿ï±âº¤ÅÍ
  • maximum gradient strength
    ÃÖ´ë°æ»ç¼¼±â, ÃÖ´ë±â¿ï±â¼¼±â
  • rephasing gradient motion
    ÀçÀ§»ó°æ»ç¿îµ¿
  • peak gradient strength
    ÃÖ°í°æ»ç¼¼±â, ÃÖ°í±â¿ï±â¼¼±â
  • aqueous flow
    ¹æ¼öÈ帧
  • axial flow
    ÃàÈ帧, Ãà·ù
  • flow artifact
    È帧Àΰø¹°, È帧Çã»ó, À¯µ¿Àΰø¹°
  • back flow
    ¿ª·ù, °Å²ÜÈ帧, µÚÈ帧
  • blood flow
    Ç÷·ù, ÇÇÈ帧
  • blood flow meter
    Ç÷·ù°è
  • blood flow rate
    Ç÷·ù·®, Ç÷·ù¼Óµµ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • phase encoding gradient
    À§»ó ºÎȣȭ °æ»çÀå
  • phase encoding gradient
    À§»ó ºÎȣȭ °æ»çµµ
  • potential gradient
    Àü¾Ð°æ»ç, ÀüÀ§°æ»ç.
  • pressure gradient
    ¾Ð·Â°æ»ç.
  • pressure gradient
    ¾Ð·Â°æ»ç
  • read gradient
    ÆÇµ¶ °æ»çµµ
  • receptor gradient
    ¼ö¿ëü°æ»ç.
  • rephasing gradient motion
    ÀçÀ§»ó °æ»ç ¿îµ¿
  • reversal of gradient
    °æ»ç¿ªÀü.
  • rewinder gradient
    µÇ°¨±â °æ»ç
  • shielded gradient
    Â÷Æó °æ»ç
  • shielded gradient coil
    Â÷Æó °æ»ç ÄÚÀÏ
  • slice selection gradient field
    ÀýÆí ¼±Åà °æ»çÀå
  • slice selection gradient(Gs)
    ÀýÆí ¼±Åà °æ»ç
  • spoiler gradient
    ȸ¼Õ °æ»ç
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • Y gradient
    YÃà °æ»ç
  • Z gradient
    ZÃà°æ»ç
  • abnormal echo
    ºñÁ¤»ó¿¡ÄÚ
  • backscatter echo
    ÈĹæ»ê¶õ¿¡ÄÚ
  • blipped echo planar single pulse
    ¼ø°£ ¿¡ÄÚÆò¸é´ÜÀÏÆÞ½º
  • bottom echo
    ¹Ù´Ú ¿¡ÄÚ
  • capsular echo
    ÇǸ· ¿¡ÄÚ
  • central renal echo complex
    ½ÅÁ߽ɿ¡ÄÚº¹ÇÕü
  • comet like echo
    Çý¼º¸ð¾ç¿¡ÄÚ
  • complex echo pattern
    º¹ÇÕ¿¡ÄÚ¾ç»ó
  • DESS [=double echo in the steady state]
    Ç×Á¤»óÅÂÀÇ ÀÌÁß¿¡ÄÚ
  • double echo T2 weighted
    ½Ö¿¡ÄÚT2°­Á¶
  • echo
    ¸Þ¾Æ¸®, ¿¡ÄÚ, ÃÊÀ½ÆÄ, ¹ÝÇâ¹Ý»ç
  • echo amplitude
    ¿¡ÄÚÅ©±â
  • echo free
    ¿¡ÄÚ°¡ ¾ø´Â, ¹«¿¡ÄÚÀÇ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
MEF maximal expiratory flow; middle ear fluid; midexpiratory flow; migration enhancement factor; mouse e...
MFR mean flow rate; mucus flow rate
MIF macrophage inhibitory factor; melanocyte[-stimulating hormone]-inhibiting factor; maximum inspirator...
MMF maxillomandibular fixation; maximum midexpiratory flow; mean maximum flow; Member of the Medical Fac...
PFR parotid flow rate; peak flow rate
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
SE Spin Echo
SEC Spontaneous echo contrast
STEAM Stimulated echo acquisition mode
TE TR)/echo time
TSE Turbo Spin Echo
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
sequence-tagged site map A map representing the order and spacing of sequence-tagged sites within a stretch of DNA.
(05 Mar 2000)
sequence tagged sites Short, tagged tracts of DNA sequence that are used as landmarks in genome mapping. In most instances, 200 to 500 base pairs of sequence define a sequence tagged site (sts) that is operationally unique in the human genome (i.e., can be specifically detected by the polymerase chain reaction in the presence of all other genomic sequences). The overwhelming advantage of stss over mapping landmarks defined in other ways is that the means of testing for the presence of a particular sts can be completely described as information in a database.
(12 Dec 1998)
sequence-tagged sites Short stretches of DNA sequences that can be detected by use of the polymerase chain reaction.
(05 Mar 2000)
pyrimidine-guanine sequence-specific ribonuclease <enzyme> From yolk granules of adult rana catesbeiana oocytes
Registry number: EC 3.1.27.-
Synonym: rc-rnase, rana catesbeiana rnase
(26 Jun 1999)
shine-dalgarno sequence A short stretch of nucleotides on a prokaryotic mRNA molecule upstream of the translational start site, that serves to bind to ribosomal RNA and thereby bring the ribosome to the initiation codon on the mRNA.
(09 Oct 1997)
signal sequence A peptide present on proteins that are destined either to be secreted or to be membrane components. It is usually at the N terminus and normally absent from the mature protein. Normally refers to the sequence (ca 20 amino acids) that interacts with signal recognition particle and directs the ribosome to the endoplasmic reticulum where co translational insertion takes place. Could also refer to sequences that direct post translational uptake by organelles. Signal peptides are highly hydrophobic but with some positively charged residues. The signal sequence is normally removed from the growing peptide chain by signal peptidase, a specific protease located on the cisternal face of the endoplasmic reticulum.
See: signal recognition particle.
(18 Nov 1997)
signature sequence Short oligonucleotides of unique sequence found in 16S ribosomal RNA of a particular group of prokaryotes.
(09 Oct 1997)
disruption sequence The events that occur when a foetus that is developing normally is subjected to a destructive agent such as the rubella (German measles) virus.
(12 Dec 1998)
DNA sequence <molecular biology> The relative order of base pairs, whether in a fragment of DNA, a gene, a chromosome, or an entire genome.
See: base sequence analysis.
(09 Oct 1997)
DNA sequence analysis <molecular biology> Determination of the nucleotide sequence of a length of DNA. Typically, this is performed by cloning the DNA of interest, so that enough can be prepared to allow the sequence to be determined, usually by the Sanger dideoxy chain temination or Maxam Gilbert chain degradation techniques. The resulting reactions are then run on a large sequencing gel, capable of resolving single nucleotide differences in chain length. Recently, PCR based methods have obviated the need to clone the DNA under some conditions and automated DNA sequencing has become widely available.
(18 Nov 1997)
DNA sequence, unstable DNA region comprised of a variable number of repetitive, contiguous trinucleotide sequences. Presence of these regions is associated with diseases such as fragile x syndrome and myotonia atrophica.
(12 Dec 1998)
insertion sequence Mobile nucleotide sequences that occur naturally in the genomes of bacterial populations. When inserted into bacterial DNA, they inactivate the gene concerned, when they are removed the gene regains its activity. Closely related to transposons and range in size from a few hundred to a few thousand bases, but are usually less than 1500 bases.
(18 Nov 1997)
intervening sequence <molecular biology> Alternative but uncommon name for an intron.
(18 Nov 1997)
tandem repeat sequence <molecular biology> Multiple copies of the same base sequence on a chromosome, used as a marker in physical mapping.
(09 Oct 1997)
termination sequence <molecular biology> The three codons, UAA known as ochre, UAG as amber and UGA as opal, that do not code for an amino acid but act as signals for the termination of protein synthesis.
They are not represented by any tRNA and termination is catalysed by protein release factors. There are two release factors in E. Coli, RF1 recognises UAA and UAG, RF2 recognises UAA and UGA. Eukaryotes have a single GTP requiring factor, eRF.
See: ochre suppressor, amber suppressor.
(13 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á